Research programme: cancer immunotherapies - Oncoresponse/Oregon Health & Science University
Latest Information Update: 28 Feb 2020
Price :
$50 *
At a glance
- Originator OncoResponse
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic myeloid leukaemia; Prostate cancer
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Chronic-myeloid-leukaemia in USA
- 28 Feb 2020 No recent reports of development identified for research development in Prostate-cancer in USA
- 08 Jan 2019 Shire has been acquired and merged into Takeda